RTP company lands work with AstraZeneca
Research Triangle Park-based G1 Therapeutics (Nasdaq: GTHX) – which raised more than $108 million in its initial public offering earlier this year – has landed work with global biopharmaceutical behemoth AstraZeneca.
G1 will collaborate with AstraZeneca on a new clinical trial evaluating AstraZeneca’s drug Tagrisso in combination with G1’s drug cand idate G1T38 for the treatment of a type of non-small cell lung cancer.
According to G1, it “will sponsor and conduct the Phase 1b/2 study…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Jennifer Henderson Source Type: news
More News: AstraZeneca | Cancer | Cancer & Oncology | Clinical Trials | Health Management | Lung Cancer | Non-Small Cell Lung Cancer